🎗️ Melanoma — 2026-W37

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Pooled individual-patient-data analysis of four randomized trials in first-line metastatic melanoma treated with nivolumab-based regimens, published in J Immunother Cancer, evaluating ORR, PFS, and time-to-next-treatment as surrogate endpoints for overall survival. Findings help determine which endpoints can reliably substitute for OS in future melanoma immunotherapy trial design.

Retrospective translational analysis in Cancer Discovery examining lymphoid aggregates in melanoma and lung adenocarcinoma brain metastases and their prognostic association. Findings are prognostic rather than predictive of a specific therapy, informing understanding of intracranial immune biology but not yet changing treatment selection.